Darzalex Triple Combo Approved in England for Difficult-to-treat Multiple Myeloma
A triple combination of Darzalex (daratumumab), Velcade (bortezomib), and dexamethasone will be available on the National Health Service (NHS) in England for…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma
Janssen has is seeking approval from the U.S. Food and Drug Administration (FDA) for Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and…
NantKwest, ProMab Partner to Develop Natural Killer Cell Therapy for Multiple Myeloma, Other Blood Cancers
NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation…
Kyprolis Combo Yields Positive Results as Initial Treatment for Multiple Myeloma
A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma,…
CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients
CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed…
Under-the-skin Formulation as Effective as Intravenous Darzalex for Myeloma Patients, Study Says
An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3…
